Drugs / Enitinostat
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06556862 | Oct 2025 → Dec 2026 expected | hormone receptor-positive breast cancer | Beijing 302 Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Enitinostat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06556862 ↗ |